|
|
| | Rodatristat) Basic information |
| Product Name: | Rodatristat) | | Synonyms: | KAR-5585
(KAR5585;Rodatristat);2,8-Diazaspiro[4.5]decane-3-carboxylic acid, 8-[2-amino-6-[(1R)-1-(5-chloro[1,1'-biphenyl]-2-yl)-2,2,2-trifluoroethoxy]-4-pyrimidinyl]-, ethyl ester, (3S)-;Rodatristat ethyl | | CAS: | 1673571-51-1 | | MF: | C29H31ClF3N5O3 | | MW: | 590.04 | | EINECS: | | | Product Categories: | | | Mol File: | 1673571-51-1.mol |  |
| | Rodatristat) Chemical Properties |
| storage temp. | Store at -20°C | | form | Solid | | color | White to off-white |
| | Rodatristat) Usage And Synthesis |
| Uses | Rodatristat is used in the method for treating interstitial lung disease using a tryptophan hydroxylase inhibitor. | | in vivo | Rodatristat ethyl (100 or 200 mg/kg; oral administration; once daily; for 28 days; male Sprague-Dawley rats) treatment decreases erum, gut and lung 5-HT levels in a dose-dependent manner and significantly reduces pulmonary arterial pressure, and pulmonary vessel wall thickness and occlusion in male rats with monocrotaline (MCT)[1]. | Animal Model: | Male Sprague-Dawley rats (175-200 g)[1] | | Dosage: | 100 mg/kg or 200 mg/kg | | Administration: |
Oral administration; once daily; for 28 days | | Result: | Decreased serum, gut and lung 5-HT levels in a dose-dependent manner and significantly reduced pulmonary arterial pressure, and pulmonary vessel wall thickness and occlusion in male rats.
|
| | IC 50 | 5-HT1 Receptor; TPH1 |
| | Rodatristat) Preparation Products And Raw materials |
|